BIG1 Fundamental Analysis - BIO-GATE AG

Fundamental Rating

We assign a fundamental rating of 3 out of 10 to BIG1. BIG1 was compared to 69 industry peers in the Chemicals industry. The financial health of BIG1 is average, but there are quite some concerns on its profitability. BIG1 is valied quite expensively at the moment, while it does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

BIG1 had negative earnings in the past year.
BIG1 had a negative operating cash flow in the past year.
BIG1 had negative earnings in each of the past 5 years.
BIG1 had a negative operating cash flow in each of the past 5 years.

1.2 Ratios

BIG1 has a worse Return On Assets (-32.97%) than 91.30% of its industry peers.
BIG1's Return On Equity of -151.10% is on the low side compared to the rest of the industry. BIG1 is outperformed by 89.86% of its industry peers.

		Industry Rank	Sector Rank
ROA	-32.97%
ROE	-151.1%
ROIC	N/A

ROA(3y)-33.66%

ROA(5y)-27.14%

ROE(3y)-61.46%

ROE(5y)-50.16%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 57.72%, BIG1 belongs to the top of the industry, outperforming 88.41% of the companies in the same industry.
BIG1's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for BIG1 so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	57.72%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-1.52%

GM growth 5Y-2.6%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

BIG1 does not have a ROIC to compare to the WACC, probably because it is not profitable.
BIG1 has about the same amout of shares outstanding than it did 1 year ago.
Compared to 5 years ago, BIG1 has more shares outstanding
There is no outstanding debt for BIG1. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -2.53, we must say that BIG1 is in the distress zone and has some risk of bankruptcy.
BIG1's Altman-Z score of -2.53 is on the low side compared to the rest of the industry. BIG1 is outperformed by 89.86% of its industry peers.
BIG1 has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	-2.53

ROIC/WACCN/A

WACC7.3%

2.3 Liquidity

A Current Ratio of 1.85 indicates that BIG1 should not have too much problems paying its short term obligations.
BIG1 has a Current ratio (1.85) which is in line with its industry peers.
A Quick Ratio of 0.55 indicates that BIG1 may have some problems paying its short term obligations.
With a Quick ratio value of 0.55, BIG1 is not doing good in the industry: 88.41% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
Current Ratio	1.85
Quick Ratio	0.55

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

BIG1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 31.80%, which is quite impressive.
The Revenue has decreased by -7.53% in the past year.
BIG1 shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.13% yearly.

EPS 1Y (TTM)31.8%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%22.52%

Revenue 1Y (TTM)-7.53%

Revenue growth 3Y4.19%

Revenue growth 5Y15.13%

Sales Q2Q%-2.1%

3.2 Future

The Earnings Per Share is expected to grow by 25.35% on average over the next years. This is a very strong growth
Based on estimates for the next years, BIG1 will show a small growth in Revenue. The Revenue will grow by 7.30% on average per year.

EPS Next Y30.3%

EPS Next 2Y31.43%

EPS Next 3Y25.35%

EPS Next 5YN/A

Revenue Next Year0.33%

Revenue Next 2Y4.18%

Revenue Next 3Y7.3%

Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BIG1. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for BIG1. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

BIG1's earnings are expected to grow with 25.35% in the coming years. This may justify a more expensive valuation.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y31.43%

EPS Next 3Y25.35%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

BIG1 does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	0%

More info and screens

Find the best dividend stocks

Show peers with best dividend

BIO-GATE AG

FRA:BIG1 (1/14/2026, 7:00:00 PM)

0.8

-0.02 (-2.44%)

Chartmill FA Rating

GICS SectorMaterials

GICS IndustryGroupMaterials

GICS IndustryChemicals

Earnings (Last)10-03 2025-10-03

Earnings (Next)02-18 2026-02-18

Inst OwnersN/A

Inst Owner ChangeN/A

Ins Owners9.8%

Ins Owner ChangeN/A

Market Cap7.39M

Revenue(TTM)6.98M

Net Income(TTM)-1.38M

Analysts82.5

Price Target3.06 (282.5%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	0%

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)-4.76%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)-15%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)-11.45%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	1.06
P/FCF	N/A
P/OCF	N/A
P/B	8.1
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-0.15

EYN/A

EPS(NY)-0.05

Fwd EYN/A

FCF(TTM)-0.09

FCFYN/A

OCF(TTM)-0.08

OCFYN/A

SpS0.76

BVpS0.1

TBVpS-0.01

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-32.97%
ROE	-151.1%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	57.72%
FCFM	N/A

ROA(3y)-33.66%

ROA(5y)-27.14%

ROE(3y)-61.46%

ROE(5y)-50.16%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y-1.52%

GM growth 5Y-2.6%

F-Score4

Asset Turnover1.67

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	30.72%
Cap/Sales	1.35%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.85
Quick Ratio	0.55
Altman-Z	-2.53

F-Score4

WACC7.3%

ROIC/WACCN/A

Cap/Depr(3y)91.79%

Cap/Depr(5y)118.01%

Cap/Sales(3y)3.64%

Cap/Sales(5y)4.33%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)31.8%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%22.52%

EPS Next Y30.3%

EPS Next 2Y31.43%

EPS Next 3Y25.35%

EPS Next 5YN/A

Revenue 1Y (TTM)-7.53%

Revenue growth 3Y4.19%

Revenue growth 5Y15.13%

Sales Q2Q%-2.1%

Revenue Next Year0.33%

Revenue Next 2Y4.18%

Revenue Next 3Y7.3%

Revenue Next 5YN/A

EBIT growth 1Y30.26%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year36.36%

EBIT Next 3Y30.3%

EBIT Next 5YN/A

FCF growth 1Y65.31%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y66.93%

OCF growth 3YN/A

OCF growth 5YN/A

BIO-GATE AG / BIG1.DE FAQ

What is the fundamental rating for BIG1 stock?

ChartMill assigns a fundamental rating of 3 / 10 to BIG1.DE.

What is the valuation status for BIG1 stock?

ChartMill assigns a valuation rating of 1 / 10 to BIO-GATE AG (BIG1.DE). This can be considered as Overvalued.

How profitable is BIO-GATE AG (BIG1.DE) stock?

BIO-GATE AG (BIG1.DE) has a profitability rating of 1 / 10.

What is the earnings growth outlook for BIO-GATE AG?

The Earnings per Share (EPS) of BIO-GATE AG (BIG1.DE) is expected to grow by 30.3% in the next year.

BIO-GATE AG (BIG1.DE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

BIO-GATE AG / BIG1.DE FAQ

What is the fundamental rating for BIG1 stock?

What is the valuation status for BIG1 stock?

How profitable is BIO-GATE AG (BIG1.DE) stock?

What is the earnings growth outlook for BIO-GATE AG?